Business Standard

Jubilant Life extends fall on weak Q4 results; stock hits 33-month low

The company had reported a net loss of Rs 101 crore Q4 FY19 on account of a one-time loan settlement with International Finance Corporation

Drugs, Pill, Medicine, Tablet
Premium

SI Reporter Mumbai
Jubilant Life Sciences shares continued to remain under pressure, hitting 33-month low of Rs 503, down 2 per cent in intra-day trade on the BSE on Wednesday. The stock has fallen 19 per cent in the past nine trading days, after reporting weak March quarter earnings. The stock was quoting at its lowest level since August 29, 2016.

The pharmaceuticals company had reported a net loss of Rs 101 crore in the fourth quarter ended March 31, 2019 (Q4FY19) on account of a one-time loan settlement with International Finance Corporation (IFC). It had posted a consolidated net profit of

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 29 2019 | 12:02 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com